Vimta Labs Ltd

- Vimta Labs has increased its overall borrowing limit from INR 175 crores to INR 300 crores as a placeholder to meet future requirements (Page 17-18). - Current capex guidance for FY 25-26 is around INR 115 crores, including INR 25 crores for biologics investment (Page 18). - While most capex will be funded through internal accruals, there may be a need to borrow INR 30-50 crores for biologics segment (Page 18). - The company states it does not intend to borrow heavily upfront and will seek necessary approvals when actual borrowing is required (Page 18). - No concrete plans announced regarding equity fundraising (Page 18). - Inorganic growth via acquisitions is a strategy but no concrete opportunities at this time (Page 18). Overall, debt limits have been prudently increased as a precaution; capital expenditure is largely planned to be internally funded with limited incremental borrowings anticipated.

- Capex guidance for FY '26 is around INR90 crores, mainly targeting equipment investment to propel growth. - Separate INR25 crores investment planned for biologics/peptide CDMO segment, over and above the INR90 crores capex. - Biologics segment capex (~INR25 crores) expected to partly require borrowing INR30-50 crores; mostly funded through internal accruals. - Recent new life sciences facility in Hyderabad commercialized; 70% capitalized; additional capacity created by shifting existing units. - Upcoming installation and qualification of electronic testing chamber expected by Q4 or early next year. - Incremental capex aims to support ~5-6 years of growth, adding lab space, equipment, and manpower progressively. - No new land parcels; expansion is within existing facilities, including some renovations for biologics CDMO services. - Borrowing power increased to INR300 crores as a placeholder to meet future capex and growth requirements without shareholder delays.

- Vimta Labs aims to achieve an exit run rate of INR125 crore per quarter by the end of FY 2025-26, reflecting significant revenue growth. - The company expects to maintain at least the same growth rate achieved in FY 2024-25 (around 19.1% year-on-year revenue growth). - Growth will be primarily driven by pharmaceutical (70% of revenue) and food testing (20% of revenue) segments. - Expansion in biologics and peptide CDMO services is underway, providing new revenue streams by backward integration of existing services. - The company anticipates continued healthy demand in pharma services, especially exports (36% of revenue), with 60% exposure to the U.S. market. - Capex of around INR90 crore planned for FY 2025-26 will further support capacity expansions to sustain growth over the next 5-6 years. - Inorganic growth through acquisitions is a strategy but currently no concrete deals. - Despite global uncertainties, Vimta expects to grow revenues with a positive outlook barring unforeseen global events.

- Vimta Labs targets reaching an INR125 crore revenue run rate by the end of FY '26 Q4, indicating strong growth momentum. - FY '25 showed robust financials with 31.2% PAT growth and steady PAT margins of 19.1%; management aims to maintain or improve margins within ±2%. - EBITDA margin in FY '25 improved due to operational efficiencies and removal of lower-margin diagnostics business. - Capex of INR90 crores planned for FY '26 (including INR50 crores for biologics CDMO) to support long-term growth and capacity expansion. - Management is optimistic about healthy demand, especially in pharmaceutical services which constitute 70% of revenues. - Repeat customer rate is strong (>90%), underlining stable revenue streams. - No explicit EPS or profit guidance given, but sustained revenue growth and margin maintenance imply improving earnings. - Inorganic growth is a strategic option but no concrete plans announced yet.

The transcript does not provide specific details on the current or expected order book or pending orders of Vimta Labs Limited. However, the following insights related to business prospects and demand can be noted: - The company is seeing traction in clinical trial RFPs with successful completion of the first trial and plans to onboard more trials during the year. - There is healthy demand in the pharmaceutical services segment, especially for small and large molecule analytical services. - Expansion and capex plans indicate preparedness for future growth but are flexible based on demand. - The management emphasizes strong repeat customer rates (upwards of 90%), reflecting good order continuity. - Export revenue (mainly pharma) is about 36%, with 60% exposure to the U.S. market. - No concrete inorganic growth opportunities or order backlog specifics were shared.